Early Chemo Linked to Improved PFS in High-Volume Metastatic Prostate Cancer


“Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival (PFS) outcomes when treated with early docetaxel, according to findings published online in the European Journal of Cancer.

“Using the Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment (Q-TWiST) method, investigators also determined that the benefits associated with androgen deprivation therapy (ADT) plus docetaxel outweighed the risks associated with the treatment.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.